Strategic Acquisition Exscientia has merged with Recursion to form a vertically integrated AI-powered drug discovery platform, representing a channel for cross-sell of combined capabilities and expanded platform access to customers seeking end-to-end AI-driven discovery solutions.

Expanded Platform Post-merger, there is potential to offer unified solutions that leverage Recursion’s scale with Exscientia’s discovery expertise, creating opportunities for larger collaborations, bundled services, and cross-selling to Sanofi and other partners in existing programs.

Financial Momentum The combined entity signals a strengthened financial profile and renewed investor interest in AI-driven drug discovery, creating a favorable environment for upsell of premium analytics, data services, and expanded collaboration milestones.

Collaborative Footprint Ongoing programs with Sanofi and other pharma partners provide access points for expanding existing collaborations, proposing additional milestone-driven initiatives, and offering enhanced translational capabilities across preclinical and lead optimization stages.

Global Reach With operations in Oxford and a broader North American technology-enabled platform, there are sales opportunities to internationalize partnerships, align regulatory-ready workflows, and deploy scalable, AI-enabled discovery suites to new geographic markets.